Skip to main content

Market Overview

UPDATE: Bank of America Downgrades Hologic to Neutral on Valuation


Bank of America downgraded Hologic (NASDAQ: HOLX) from Buy to Neutral and raised the price target from $23.00 to $24.00.

Bank of America noted, "We are downgrading Hologic to Neutral driven largely by valuation following a 22% increase since early December (vs the medical device group up 10%). While we're raising our PO slightly to $24 (from $23), we find it difficult to justify a higher valuation without expecting meaningful upside to 2013 estimates, which we believe is unlikely. On the top-line, both guidance and consensus for 2013 call for pro forma revenue growth of 5-6%, which implies an acceleration from the 3% level seen in fiscal Q1 to 6-8% in the back half of the year."

Hologic closed at $22.75 on Tuesday.

Latest Ratings for HOLX

Apr 2021JefferiesMaintainsBuy
Feb 2021BairdMaintainsBuy
Dec 2020Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings


Related Articles (HOLX)

View Comments and Join the Discussion!

Posted-In: Bank of AmericaAnalyst Color Downgrades Analyst Ratings

Latest Ratings

VZIOWells FargoInitiates Coverage On31.0
OMWells FargoInitiates Coverage On63.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at